In vivo prothrombin activation is thought to occur via a factor XJfactor V-dependent mechanism.
NTRAVASCULAR GENERATION of thrombin is a key event in hemostasis. In addition to its role in promoting blood coagulation and platelet activation,' thrombin also initiates anticoagulation via the protein C pathway' and possesses a variety of other effects on vascular biology, including mitogenesis, chemotaxis, and ather~genesis.~.~ Prothrombin activation may occur by a number of mechanisms. The most important mechanism for in vivo prothrombin activation is thought to be dependent on factors X, and V,. The assembly of the prothrombinase complex (factor V,, factor X., prothrombin, and calcium) on phospholipid and cellular surfaces serves to localize thrombin formation and to optimize the rate of prothrombin activation.6 Factors V,/X,-catalyzed prothrombin activation can occur on a variety of cell surfaces, including platelets,' monocytes,* and endothelial cells (EC). 9 Other activators of prothrombin include certain snake venoms, such as the activator of Echis curin~tus,'~ as well as an inducible prothrombin activator observed in monocytes. " Recently, an additional mechanism for thrombin formation was described in which a membrane-associated protease activated prothrombin independent of factors X, and V,. This activity was identified in nonvascular cell lines and had properties of a metalloproteinase." The purpose of the present study was to determine whether human venous EC could be induced to express a prothrombin activator, and if so, to characterize this vascular procoagulant property,
I

MATERIALS AND METHODS
Tissue culture plastic ware was obtained from Falcon Plastics (Oxnard, CA). Trizma base, lipopolysaccharide (from Escherichia coli serotype 055:B5), ammonium sulfate, polyethylene glycol, diisopropylfluorophosphate (DFP), phenylmethylsulfonyl fluoride (PMSF), bovine fibrinogen, cycloheximide, and reagents used for buffers and gel electrophoresis were supplied by Sigma Chemical CO (St Louis, MO). Dansyl-Glu-Gly-Arg chloromethyl ketone and a chromogenic substrate for factor X, were purchased from Calbiochem (La Jolla, CA). Fetal bovine serum was supplied by HyClone (Logan, UT). Medium 199 and other tissue culture reagents were provided by GIBCO (Grand Island, NY). Interleukin-lp (IL-lp) was supplied by Genzyme (Boston, MA). Purified coagulation proteins (prothrombin, factors X. and V, protein S, activated protein C) and antibodies to factor V and factor X were obtained from Haematologic Technologies (Essex Junction, VT). The antibody to factor X was a murine monoclonal that recognized the heavy chain of factor X (X,) and inhibited prothrombinase activity. The antibody to factor Blood, Vol 88, No 8 (October 15). 1996: pp 2989-2994 tor X inhibited prothrombin activation. However, the EC activator did not hydrolyze a factor X. chromogenic substrate, and recombinant tick anticoagulant peptide did not suppress activity of the prothrombin activator. The apparent molecular weight of the EC activator was -30 kD. Exogenous factor V enhanced the activity of the EC activator, such that in the presence of factor V, the apparent Km value was 1.28 k 0.10 pmol/L. Additionally, LPS-treated EC activated exogenous factor V. This activator has several characteristics of a previously described inducible murine monocyte prothrombin activator and may contribute to thrombin generation associated with pathologic stimuli. 0 1996 by The American Society of Hematology.
V was a murine monoclonal that recognized the light chain of factor V and that inhibits prothrombinase.'' Control murine monoclonal antibodies of identical isotype were obtained from Ancell (Bayport, MN). A silver stain kit for identifying proteins in gels was obtained from Bio-Rad (Richmond, CA). '"1 was supplied by Amersham Corp (Clearbrook, IL), and Iodogen was purchased from Pierce Chemical CO (Rockford, IL). Elution of proteins from gel slices was performed according to the instructions of the manufacturer using a Centrilutor apparatus from Amicon (Beverly, MA). L-a-phosphatidylserine and L-a-phosphatidylcholine were supplied by Avanti Pol a r Lipids (Alabaster, AL). Purified human a-thrombin (2,678 U/ mg) was kindly provided by Dr John W. Fenton I1 (New York State Department of Health, Albany, NY), and recombinant tick anticoagulant peptide (TAP) was provided by Dr S. Krishnaswamy (Emory University, Atlanta, GA). Clotting times were determined using a fibrometer (BBL, Cockeysville, MD).
Human umbilical vein endothelial cells were prepared as described.14 EC were plated in 24-well trays (17-mm diameter; each well contained 86,000 I 4,000 [SEMI cells), or 100-mm dishes, and were used during the first passage. To determine whether EC could be induced to express a prothrombin activator, cultured EC were treated either with lipopolysaccharide (LPS) or IL-lp in Medium 199 containing 20% serum. At intervals, the cells were washed, then incubated with 20 mmol/L Tris and 150 mmol/L NaCl (pH, 7.4; TBS) containing prothrombin (140 pg/mL) for 2 hours. Aliquots of this latter incubation were removed and assayed using a thrombin time clotting assay." Clotting times were converted to thrombin concentrations (ng/mL) using a purified standard of human a-thrombin.
Thrombin formation by normal EC and factors X,N was compared with that by LPS-treated EC. Control EC were incubated with factor X, (20 ng/mL), and factor V (6 pg/mL), prothrombin (140 For personal use only. on September 14, 2017. by guest www.bloodjournal.org From pg/mL) in TBS, with or without an antibody to factor V (100 pg/ mL). LPS-treated EC were incubated with TBS and prothrombin (140 pg/mL), with or without an antibody to factor V (100 wg/mL). Aliquots were removed at 5, 30, 60, and 120 minutes to quantitate thrombin generation.
Prothrombin was iodinated using the Iodogen methodi6 by incubating 0.5 mg protein at 4°C with 1 mCi of l 2 ' I in an Iodogen-coated Eppendorf tube. After 20 minutes, the radiolabeled prothrombin was separated from unincorporated iodine by using gel filtration chromatography. The specific activity of the radiolabeled protein ranged between 10 to 20 X lo6 cpm/pg. A functional assay show that the activity of "'I-prothrombin was equivalent to that of unlabeled prothrombin. Phospholipid vesicles were prepared by mixing 1 mg phosphatidylserine with 3 mg phosphatidylcholine in 1 mL TBS and sonicating for 30 minutes at 30% duty cycle. The sample was maintained in an ice bath under a nitrogen stream during this period. After sonication, liposomes were filtered using a 0.45-pm filter." To determine whether certain protease inhibitors could affect activity of the EC activator, EC prothrombin activator activity was extracted from LPS-treated EC (1 molL NaCI, 30 minutes); extracts were subsequently dialyzed against TBS before the assay.
To determine whether protein synthesis was required for induction of the prothrombin activator, EC were pretreated with TBS or cycloheximide (10 pg/mL) 2 hours before addition of LPS. Thrombin generation was then measured as described above.
A comparison of '"I-prothrombin cleavage products generated by normal EC and factors X,N versus LPS-treated EC was performed. Aliquots of incubations were analyzed by reduced-sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (10%) and autoradiography.
The molecular weight of the prothrombin activator was estimated using gel slicing and bioassay. LPS-treated EC (six 100-mm dishes)
were extracted with high salt ( 1 mom NaCI). The extract was dialyzed against TBS, and then 100 pgllane were applied to a 10% nonreduced SDS gel. The completed gel was sliced into OS-cm segments and eluted into TBS using a Centrilutor apparatus. Eluates were then assayed for prothrombin activation and an apparent molecular weight estimated for the biologically active fraction.
To determine whether LPS-treated EC could activate factor V, EC were incubated either with control media or LPS-containing media (1 pg/mL) for 4 hours, washed with M199, then incubated with M199 containing factor V (2 pg/mL) for 2 hours. The supernatants were removed, centrifuged at lO,OOOg, and assayed for factor V (V.) activity. The cell monolayers were washed three times with TBS, and 0.1 mL TBS was added to each dish. The cells were then scraped from the dish, transferred to Eppendorf tubes, rapidly frozen at -70°C and assayed for factor V (V,) activity. Supernatant factor V (V,) activity was expressed as milliunits (mU)/mL, with 1 U representing the activity in I mL of pooled human plasma. Cell lysate activity was expressed as mU/dish.lx Factor V antigen levels were measured using a previously-described radioimmunoassay.'' Control or LPS-treated (1 pg/mL, 4 hours) EC were washed, then solubilized with 1% Triton X-100, and centrifuged at 15,000g for 30 minutes to remove insoluble material. Iodination of factor V, construction of the factor V standard curve, and sample incubation were conducted as described." EC factor V antigen levels were expressed as ngldish.
Kinetic analysis was performed using a modified Gauss-NewtonMarquardt-Levenberg nonlinear least-squares procedure, as previously described."
RESULTS
In initial experiments, we observed that when LPS-treated 0.8 mmoVL magnesium. Maximal thrombin formation occurred with EC treated with LPS (1 pg/mL; 4 hours), or with IL-lD (10 U/mL; 4 hours). When LPS-treated EC were subsequently incubated with 140 pg/mL prothrombin, 5 mmol/L calcium, and 0.8 mmoVL magnesium, 6 nmoV L thrombin was generated after 2 hours. When LPS-EC lysates were subjected to ultracentrifugation (at 100,OOOg for 1 hour), 95% of the prothrombin activator activity resided in the membrane fraction. The prothrombin activator was characterized using protease inhibitors and was compared in two model systems. In one model, the effects of factor X, inhibitors on the activity of the inducible EC prothrombin activator were compared with control EC and classical prothrombinase (factors X,N) using equivalent EC surface areas. In a second model, the inducible EC prothrombin activator was compared with a standard system of phospholipid and factors X J V such that both generated equivalent amounts of thrombin. The results of two comparative studies are summarized. The left side compares the effects of factor X. inhibitors on thrombin generation in the LPS-EC model v an equivalent surface area of control EC with factors X&. Reactant concentrations were as follows: LPS-EC experiment: factor V (6 pg/mL), prothrombin (140 pg/mL); control €C/ XJV: factor V (6 pg/mL), prothrombin (140 pg/mL), factor X. (20 ng/ mL); PVXJV: factor V (6 pg/mL), prothrombin (140 pg/mL), factor X. Results shown are the mean of duplicate experiments.
In this experiment, prothrombin activator activity was extracted from EC as described in Materials and Methods, treated with the protease inhibitor and subsequently incubated with prothrombin. Fig 2. Comparison of the '=I-prothrombin cleavage products generated by control EC and factors X. / V versus LPS-treated EC. Control EC were incubated with factor X. (20 ng/mL), factor V (6 pg/mL), and prothrombin (140 pg/mL) in TBS. LPS-€C were incubated with prothrombin (140 pg/mL) in TBS. Aliquots were removed at intervals and subjected t o and an antibody to factor X inhibited thrombin generation by LPS-EC and control ECIXJV equivalently, r-TAP was less effective in inhibition of thrombin formation by LPS-EC. Similar inhibition results were observed when lower anti-factor X antibody concentrations were tested. A 10-pg/mL antibody concentration reduced LPS-EC thrombin formation by 29%. while reducing control EC/X,N thrombin formation by 11%. At 25 pg/mL antibody concentration, LPS-EC was inhibited by 53%, whereas control ECIXJV was inhibited 45%. At 50 pg/mL antibody concentration, LPS-EC was inhibited 85%, whereas control EC/X,N was inhibited 99%. An antibody to factor V did not affect LPS-EC activity but did reduce prothrombinase activity by 290%. When isotype control monoclonal antibodies were tested in similar concentrations, no inhibition of thrombin generation was seen in either model. The effects of PMSF also differed, in that LPS-EC were more sensitive to this protease inhibitor than prothrombinase. LPS-EC generated 6% of thrombin generated by control EC and factors XJV. Incubation of LPS-EC with activated protein C (IO pg/mL) reduced thrombin generation by 47%.
tor V. t This experiment was performed in the absence of exogenous Fac
Incubation of LPS-EC or an extract of LPS-EC with a chromogenic substrate for factor X, resulted in no substrate hydrolysis. These results suggest that the EC activator has serine protease characteristics (inhibition by PMSF), and may resemble factor X, in certain respects (inhibition by DEGRchloromethyl ketone, a specific factor X. inhibitor, inhibition by an antibody to factor X). 
0.4
Experiments were conducted as described in Materials and Methods using control EC, prothrombin (140 pg/rnL) and factors XJV concentrations indicated in the table. Results shown are the mean of duplicate experiments. A factor X, concentration of 20 ng/mL and factor V concentration of 6 pg/mL was arbitrarily defined as 100% (saturating levels).
mide (10 pg/mL) resulted in < O S nmoVL thrombin generated.
Factor V, is a cofactor for factor X,-catalyzed prothrombin activation. We investigated whether exogenous factor V would enhance activity of the inducible prothrombin activator. Figure 3 shows prothrombin concentration-response curves in which control EC incubated with factors X,N and prothrombin ( Fig 3A) were compared with LPS-EC incubated with factor V and prothrombin (Fig 3B) . The apparent Km of control EC and prothrombinase was 1.07 2 0.06 pmol/L; the apparent Km of LPS-EC incubated with factor V and prothrombin was 1.28 ? 0.10 pmoVL.
To compare endothelial cell-dependent prothrombin activation in the control and LPS-EC models, experiments were performed with and without saturating levels of factors X:,/ V and control EC (Table 2) . Three concentrations of factors X,N were tested, 20 ng/mL X,:6pg/mL V ( 1 OO%), I O ng/ m1 X;,:3 pg/mL V (50%), and 2 ng/mL X,:0.6 pg/mL V (10%). As shown in Table 2 , thrombin generation was directly related to concentrations of factors XaN. Comparison of thrombin generation by LPS-EC with exogenous factor V (468 nmol/L thrombin formed) with the data of Table  2 indicates that the inducible prothrombin activator (with exogenous factor V) generated 4 1 % of thrombin generated by control EC and prothrombinase.
In the prothrombinase reaction, factor V, is thought to be initially generated from factor X, activation of factor V' "; factor V, then mediates factor X,-catalyzed prothrombin activation. We tested the hypothesis that LPS-EC could also activate factor V, to provide an activated cofactor for the inducible prothrombin activator. Exogenous factor V was incubated with control or LPS-EC, and factor V (V,) activity measured in supernatants and cell lysates by clotting assay. Control supernatants possessed 388 t-43 mU/mL factor V (V,) activity, whereas LPS-EC supernatants showed 4,650 t-300 mU/mL activity. Control cell lysates possessed 303 t-31 mU/dish factor V(V,) activity, whereas LPS-EC lysates showed 3,980 -t 103 mU/dish activity. Radioimmunoassay of EC factor V antigen levels showed control EC to have 69 ? 4 ng/dish (n = 4) and LPS-EC to have 71 t-2 ng/dish (n = 4). These data suggest that LPS-EC can activate factor V. Figure 4 shows a molecular weight estimation of the inducible prothrombin activator, as deduced from a gel-slice elution study from a nonreduced gel. Peak thrombin generation occurred with gel slices associated with an apparent molecular weight of -30 k D .
DISCUSSION
Thrombin possesses multiple biological activities, including promotion of coagulation, platelet aggregation, as well as modulation of vessel wall tone, and inflammation. Within the vasculature, prothrombinase (factors X,, V,, calcium, prothrombin) is considered to be the major mechanism for prothrombin activation. 6 The recent discovery of a membrane-associated protease that activates prothrombin in the absence of factors X$Vl2 led us to investigate whether vascular endothelium might be induced to express a similar activator.
The data presented in this study indicate that human EC can be induced by relevant pathologic stimuli (LPS, IL-I@) to express a prothrombin activator. There are similarities between the vascular and nonvascular activators, as well as differences. Similarities include membrane localization and a requirement for calcium. The vascular activator differs from the nonvascular activator'' in that the former is inducible (v constitutive) and has a lower molecular weight (30 v 70 m). The inducible activator also has similarities and differences to factor X, (Table 1) . For example, dansyl-GluGly-Arg chloromethyl ketone and an antibody to factor X inhibit both the inducible activator and prothrombinase. However, factor X, has a molecular weight of 48 k D , whereas the inducible activator has a molecular weight of -30 k D , and the prothrombin activator was more sensitive to PMSF inhibition than factor X,. Additionally, the inducible activator is membrane-associated, whereas factor X, is a plasma protease, and the activator did not hydrolyze a substrate specific for factor X,. TAP also inhibited factor X,-catalyzed prothrombin activation to a greater extent than the inducible activator.
The inducible EC activator also has properties similar to those of the murine monocyte enzyme." The monocyte enzyme cleaved prothrombin in a similar manner as factor X,, was membrane associated, required induction by LPS or immune complexes, required calcium for maximal activity, and showed characteristics of a serine protease." The investigators of the murine monocyte enzyme did not identify enhancement of activity by factor V or report a molecular weight." Defining whether the inducible activator is factor X, or a different protease awaits structural data on the purified protein. Our current data suggests that the inducible prothrombin activator has factor X,-like activity.
Although an antibody to factor V did not inhibit prothrombin activation by LPS-EC, exogenous factor V enhanced activity of the inducible activator, and activated protein C reduced activity of the activator. Human umbilical vein EC2' and bovine aortic ECZ2 do synthesize factor V, and it is possible that basal activity of the inducible activator is dependent on EC-synthesized factor V (Va). In addition to activating prothrombin, LPS-treated EC also activated exogenous factor V 12-fold. Future studies using the purified prothrombin activator will permit us to show whether this protease is responsible for both prothrombin activation and factor V activation.
What are the implications of an inducible vascular prothrombin activator? Tissue factor-initiated factor X activation and subsequent factor X,-catalyzed prothrombin activation would be downregulated by tissue factor pathway inhibit~r.'~ Although thrombin produced by the tissue factor mechanism might initiate intrinsic coagulation to generate additional induction of a vascular cell prothrombin activator would also provide a source of thrombin activity associated with pathologic stimuli. It is notable that in a study by Levi et alZ5 in which primates were infused with endotoxin and parameters of activation of coagulation measured, the authors found paradoxical data regarding factor X activation in vivo (no factor IX or X activation peptides generated after endotoxin infusion), leading them to postulate that "other mechanisms coupled with tissue factor expression are required for endotoxin-induced prothrombin activation in vivo."25 The inducible prothrombin activator may constitute one of these mechanisms. Future studies will be directed toward purifying and identifying this procoagulant molecule. 
